Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design

BACKGROUND: Carcinoma of unknown primary origin (CUP) accounts for 2%–5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or im...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Jeffrey S., Sokol, Ethan S., Moch, Holger, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Beringer, Andreas, Thomas, Marlene, Elvin, Julia A., Ngo, Nhu, Jin, Dexter X., Krämer, Alwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Diagnostics and Molecular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930409/
https://www.ncbi.nlm.nih.gov/pubmed/33219618
http://dx.doi.org/10.1002/onco.13597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930409/
https://www.ncbi.nlm.nih.gov/pubmed/33219618
http://dx.doi.org/10.1002/onco.13597

Ejemplares similares